RMTI
Rockwell Medical, Inc. NASDAQ Listed Jan 27, 1998$0.67
Pre-mkt
$0.64
-4.04%
Mkt Cap $24.0M
52w Low $0.62
3.7% of range
52w High $1.83
50d MA $0.79
200d MA $0.99
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.3x
ROE
-14.4%
P/FCF
-20.0x
RSI (14)
43.10
ATR (14)
$0.04
Beta
1.71
50d MA
$0.79
200d MA
$0.99
Avg Volume
298.5K
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
30142 South Wixom road · Wixom, MI 48393 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 0.81 | -1.5% | -3.6% | +6.8% | +0.6% | +0.6% | -5.0% | — |
| Mar 26, 2026 | AMC | 0.04 | -0.01 | -125.0% | 0.94 | -1.3% | -7.6% | -2.3% | +5.1% | +4.5% | +2.5% | — |
| Nov 12, 2025 | AMC | -0.04 | -0.05 | -25.0% | 0.96 | +2.6% | -4.5% | +0.7% | -5.8% | +1.1% | -1.8% | — |
| Aug 14, 2025 | AMC | -0.05 | -0.05 | +0.0% | 1.05 | +1.0% | -2.9% | +2.9% | +0.0% | +0.0% | +10.5% | — |
| May 12, 2025 | AMC | -0.03 | -0.04 | -33.3% | 1.04 | +1.9% | +2.9% | -5.6% | -3.0% | +3.1% | +3.0% | — |
| Mar 20, 2025 | AMC | 0.02 | -0.02 | -200.0% | 1.40 | -0.7% | -3.6% | -6.7% | -4.8% | +3.3% | -3.2% | — |
| Nov 12, 2024 | AMC | 0.01 | 0.05 | +400.0% | 2.83 | +6.0% | -7.1% | -5.3% | -5.2% | -0.4% | +6.0% | — |
| Aug 8, 2024 | AMC | 0.00 | 0.01 | +126.4% | 2.14 | +2.8% | +1.4% | +9.7% | +0.8% | -1.7% | +8.5% | — |
| May 14, 2024 | AMC | -0.05 | -0.02 | +60.0% | 1.70 | -1.8% | +0.6% | +1.8% | +1.7% | +1.7% | +0.0% | — |
| Mar 21, 2024 | AMC | -0.08 | 0.02 | +125.0% | 1.52 | -4.6% | +12.5% | -5.3% | +1.9% | -0.6% | +1.2% | — |
| Nov 14, 2023 | AMC | -0.12 | -0.07 | +41.7% | 1.96 | +3.1% | +12.8% | -6.8% | +0.5% | -5.8% | -2.6% | — |
| Aug 14, 2023 | AMC | -0.12 | -0.18 | -50.0% | 2.85 | -1.1% | -3.2% | -18.1% | -2.2% | +0.0% | +5.9% | — |
| May 15, 2023 | AMC | -0.18 | -0.10 | +44.4% | 2.41 | +2.9% | -2.9% | -0.9% | +1.7% | +0.0% | +8.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.87 | $0.86 | -0.9% | -2.3% | +5.1% | +4.5% | +2.5% | +0.8% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.15 | $1.15 | +0.0% | -5.2% | +5.5% | -1.7% | -3.5% | -1.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.96 | $0.98 | +2.6% | -4.5% | +0.7% | -5.8% | +1.1% | -1.8% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.35 | +0.0% | -6.7% | -4.8% | +3.3% | -3.2% | -5.0% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.08 | $2.08 | +0.0% | +1.4% | +1.9% | +0.5% | -0.9% | -4.2% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.25 | $2.30 | +2.2% | +2.7% | -2.6% | -1.3% | +3.2% | -2.2% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.17 | $2.23 | +2.8% | +9.7% | +0.8% | -1.7% | +8.5% | +0.8% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.73 | +1.2% | +1.8% | +1.7% | +1.7% | +0.0% | +0.6% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.71 | $1.68 | -1.8% | -5.3% | +1.9% | -0.6% | +1.2% | +2.4% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.96 | $2.02 | +3.1% | +12.8% | -6.8% | +0.5% | -5.8% | -2.6% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.05 | -0.5% | +0.5% | +3.4% | +7.0% | -5.7% | +13.0% |
| Sep 28 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $1.85 | $1.85 | +0.0% | +8.1% | +4.0% | -2.4% | +1.5% | +0.5% |
| Sep 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.85 | +0.0% | +8.1% | +4.0% | -2.4% | +1.5% | +0.5% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.85 | $2.82 | -1.1% | -3.2% | -18.1% | -2.2% | +0.0% | +5.9% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.49 | +9.4% | +31.3% | -4.1% | +9.0% | -7.3% | -0.7% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.39 | $2.47 | +3.3% | +13.0% | +23.0% | +11.7% | +13.7% | +8.1% |
| May 30 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.39 | $2.47 | +3.3% | +13.0% | +23.0% | +11.7% | +13.7% | +8.1% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.94 | $2.98 | +1.4% | -1.7% | +3.1% | -3.0% | -0.7% | +0.0% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.80 | +0.0% | +3.9% | -2.7% | +0.0% | +8.8% | +3.0% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.27 | +5.6% | +10.2% | +5.5% | +4.8% | -2.7% | -1.6% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.90 | $1.86 | -2.1% | +2.1% | +0.5% | +10.3% | +10.2% | +5.5% |
| Aug 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.57 | +10.6% | +12.7% | +13.1% | +2.8% | -9.1% | -4.7% |
| Jan 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.17 | $4.73 | -8.5% | +0.0% | +8.5% | -7.8% | -17.0% | -2.6% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.04 | $7.15 | +1.6% | +3.1% | -3.0% | -3.1% | +4.8% | -4.6% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.07 | $15.84 | +5.1% | +8.0% | +30.4% | -6.2% | -6.1% | +2.9% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.99 | $23.32 | +1.4% | -3.8% | +5.5% | +5.2% | +9.9% | +2.4% |
| Nov 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $21.01 | $21.34 | +1.6% | +2.6% | +2.6% | +4.5% | -0.5% | -1.9% |
| Jun 25 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $32.56 | $33.44 | +2.7% | +4.7% | -3.5% | +0.3% | +0.3% | -0.7% |
| Jun 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $32.89 | $34.10 | +3.7% | -1.0% | +4.7% | -3.5% | +0.3% | +0.3% |
| Oct 19 | IFS Securities | Downgrade | Strong Buy → Outperform | — | $47.19 | $46.64 | -1.2% | -1.2% | +1.4% | +0.7% | -4.4% | +4.1% |
| Aug 14 | IFS Securities | Downgrade | Strong Buy → Buy | — | $68.64 | $69.96 | +1.9% | +5.0% | -2.1% | +0.3% | -3.6% | +1.5% |
| Nov 8 | BofA Securities | Downgrade | Neutral → Underperform | — | $62.26 | $44.00 | -29.3% | -20.3% | +8.9% | +4.1% | +7.0% | +4.2% |
| Aug 19 | BTIG Research | Maintains | Buy → Buy | — | $81.07 | $82.17 | +1.4% | -2.0% | +0.0% | +0.4% | -1.2% | -2.5% |
| Mar 1 | Craig-Hallum | Downgrade | Buy → Hold | — | $105.60 | $67.10 | -36.5% | -34.3% | -1.3% | -2.1% | +1.5% | +4.8% |
| Mar 1 | Stifel | Downgrade | Buy → Hold | — | $105.60 | $67.10 | -36.5% | -34.3% | -1.3% | -2.1% | +1.5% | +4.8% |
| Aug 13 | Morgan Stanley | Maintains | Underweight → Underweight | — | $151.14 | $134.53 | -11.0% | -16.0% | +9.6% | -0.1% | -4.1% | -3.5% |
| Jan 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $104.61 | $111.65 | +6.7% | +8.7% | +5.0% | +0.1% | +8.6% | -0.1% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $102.63 | $127.82 | +24.5% | +13.1% | +3.3% | +2.3% | +0.8% | -2.0% |
| Aug 14 | FBR Capital | Maintains | Underperform → Underperform | — | $122.65 | $115.39 | -5.9% | -7.9% | -0.3% | +1.5% | -0.8% | -2.0% |
| Dec 19 | Chardan Capital | Maintains | Buy → Buy | — | $115.72 | $120.01 | +3.7% | +6.0% | +2.5% | -2.0% | -0.7% | +0.6% |
| Dec 17 | Brean Capital | Maintains | Sell → Sell | — | $148.17 | $127.27 | -14.1% | -19.8% | -2.6% | +6.0% | +2.5% | -2.0% |
| Sep 13 | Craig-Hallum | Maintains | Buy → Buy | — | $90.53 | $98.01 | +8.3% | +22.8% | -1.1% | -2.3% | -0.2% | -3.7% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $43.56 | $45.65 | +4.8% | -4.8% | +3.4% | -4.1% | -4.0% | -6.7% |
| Nov 27 | Dawson James | Maintains | Market Outperform → Outperform | — | $79.75 | $79.86 | +0.1% | -1.8% | -0.6% | +1.0% | +1.8% | +0.0% |
| Nov 9 | Stifel | Maintains | Buy → Buy | — | $73.04 | $72.05 | -1.4% | -3.8% | -1.6% | +1.6% | -5.9% | -7.0% |
| Apr 11 | Summer Street | Maintains | Buy → Buy | — | $97.35 | $99.11 | +1.8% | +7.9% | -2.2% | -2.2% | +1.1% | +1.5% |
| Mar 12 | Stifel | Maintains | Buy → Buy | — | $98.67 | $103.07 | +4.5% | +8.6% | +0.8% | -6.3% | +6.0% | -2.9% |
No insider trades available.
8-K
Rockwell Medical, Inc. -- 8-K Filing
Rockwell Medical, Inc. (RMTI) filed an 8-K confirming its Delaware incorporation and tax identification details, indicating routine corporate documentation update with no material business impact.
Jun 15
8-K · 2.02
!! High
Rockwell Medical, Inc. -- 8-K 2.02: Earnings Results
Rockwell Medical reported Q1 2026 financial results, providing investors with updated insights into the company's operational performance and financial condition for the quarter.
May 7
8-K
Rockwell Medical, Inc. -- 8-K Filing
May 7
8-K
Unknown — 8-K Filing
RMTI experienced a material triggering event requiring immediate disclosure, making this 8-K critical for understanding recent developments that could significantly impact the stock's valuation and investor decision-making.
Mar 26
8-K
Unknown — 8-K Filing
Rimini Street (RMTI) achieved sustained profitability with $69.3M revenue in 2025, demonstrating business model viability and potentially supporting stock valuation multiples expansion if growth accelerates.
Mar 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 1,182,361 | $1M | New | Mar 2026 |
| 2 | Renaissance Technologies Llc | 639,120 | $571K | Added | Mar 2026 |
| 3 | Ubs Group Ag | 178,886 | $160K | Added | Mar 2026 |
| 4 | Wealthspire Advisors, Llc | 151,838 | $136K | New | Mar 2026 |
| 5 | Northern Trust Corp | 104,523 | $93K | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 101,079 | $84K | New | Dec 2025 |
| 7 | Hightower Advisors, Llc | 93,524 | $78K | — | Dec 2025 |
| 8 | Panagora Asset Management Inc | 69,726 | $62K | Added | Mar 2026 |
| 9 | Corsair Capital Management, L.p. | 35,000 | $42K | Reduced | Sep 2025 |
| 10 | Prudential Financial Inc | 35,800 | $32K | New | Mar 2026 |
| 11 | Richmond Brothers, Inc. | 30,611 | $26K | Reduced | Dec 2025 |
| 12 | Beacon Financial Advisory Llc | 24,645 | $22K | — | Mar 2026 |
| 13 | Hrt Financial Lp | 12,762 | $11K | New | Mar 2026 |
| 14 | Mutual Advisors, Llc | 12,000 | $11K | — | Mar 2026 |
| 15 | Commonwealth Equity Services, Llc | 10,129 | $8K | — | Dec 2025 |
| 16 | Morgan Stanley | 7,084 | $6K | Reduced | Dec 2025 |
| 17 | Wells Fargo & Company/mn | 4,987 | $4K | New | Mar 2026 |
| 18 | Vermillion Wealth Management, Inc. | 360 | $322 | — | Mar 2026 |
| 19 | Comerica Bank | 163 | $136 | — | Dec 2025 |
| 20 | Jpmorgan Chase & Co | 35 | $30 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 188,644 | $170K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 86,425 | $77K | Mar 2026 |
| 3 | Fidelity Total Market Index Fund | 52,325 | $47K | Feb 2026 |
| 4 | Fidelity Series Total Market Index Fund | 47,958 | $43K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 17,380 | $16K | Feb 2026 |
Valuation
Market Cap
$24.0M
Enterprise Value
-$24.96B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.01x
P/B
0.65x
P/S
0.35x
P/FCF
-19.99x
EV/EBITDA
—
Shares Out
36.0M
Financials (TTM)
Revenue
$67.7M
Net Income
-$5.4M
EBITDA
-$2.6M
Free Cash Flow
-$1.2M
Op Cash Flow
-$659K
EPS Basic
$-0.15
EPS Diluted
$-0.15
EPS Forward
$-0.07
Gross Margin
17.1%
Op Margin
-7.1%
Net Margin
-8.0%
Balance Sheet
Total Assets
$57.1M
Total Liab.
$20.2M
Total Equity
$37.0M
Cash
$25.00B
LT Debt
$8.8M
Book Value/Sh
$1.03
Debt/Equity
0.34x
Current Ratio
3.98
Quick Ratio
3.63
Returns & Growth
ROE
-14.4%
ROA
-9.3%
ROIC
-9.5%
Rev Growth YoY
-31.8%
EPS Growth YoY
-495.2%
Price Returns
2W
-6.7%
1M
-15.2%
3M
-17.4%
6M
-25.3%
12M
-24.4%
Technicals
52W High
$1.83
52W Low
$0.62
50d MA
$0.79
200d MA
$0.99
RSI (14)
43.10
ATR (14)
$0.04
Beta
1.71
Avg Volume
298K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$3.00
Low
$3.00
Median
$3.00
Data updated apr 26, 2026 11:11pm
· Source: financialmodelingprep.com